PRESS RELEASE

May 6, 2024 – New York, NY -- Information Mediary Corp (IMC) and Adherence have
collaborated to introduce a digitized Morisky Medication Adherence Scale (MMAS),
revolutionizing medication adherence management. This innovative solution signifies a
significant advancement in precision and efficiency in patient care.

The Morisky scale plays a crucial role in ensuring patients adhere to their prescribed
medications, directly impacting treatment outcomes by preventing disease progression,
reducing complications, and enhancing overall health outcomes.

Recognized as the gold standard for assessing medication adherence, the MMAS-4 and
MMAS-8 have been referenced in over 31,298 academic journals.

This new partnership combines IMC’s cutting-edge dose analytics with Adherence's
expertise to create a solution that integrates patient-reported MMAS data with objective
adherence information. Through this collaboration, IMC will seamlessly integrate MMAS
with the CertiScan® Adherence Insight Platform, eCap™ Smart Bottle Cap, and Med-ic®, providing partners with a comprehensive suite of tools for advanced adherence monitoring and improved
patient outcomes.

A key focus of this partnership is the development of APIs for third-party platform
integration. This initiative will enable industry partners to leverage the benefits of this
innovative solution across various healthcare setting.

Dean Brotzel, CTO of IMC, emphasized, “The digital MMAS integration marks a
significant milestone in medication adherence monitoring. By leveraging combined data
sources, we are transforming the approach healthcare providers and patients take
towards medication adherence.”

For media inquiries or more information on the groundbreaking collaboration between
IMC and Adherence, please contact dbrotzel@informationmediary.com or
Philip.morisky@adherence.cc

About Information Mediary Corp (IMC): IMC is at the forefront of developing smart
packaging solutions that integrate cutting-edge technology to enhance patient safety,
medication adherence, and healthcare outcomes.

IMC’s Med-ic® is the only Smart Dose blister ever submitted with a FDA priority review
resulting in a blockbuster drug approval. Over a million smart Med-ic® blisters have been
used over the past few years to gather valuable adherence data from over 20 million
doses in pivotal clinical trials with customers such as AbbVie and Merck.
InformationMediary.com

About Adherence: The MMAS (Morisky Medication Adherence Scale), developed by
Dr. Donald Morisky and several co-authors, is a 4 and 8 item self-report Morisky
Medication Adherence Scales questionnaire that evaluates medication adherence by
probing behaviors like medication forgetting or discontinuation. The MMAS is widely
applied in healthcare research and clinical practice, aiding in the identification of
patients at risk of non-adherence and guiding the customization of adherence
interventions.

Adherence serves as the catalyst with pharmaceutical firms, telehealth initiatives, and IT
platforms seamlessly integrating MMAS into their systems and procedures. MMAS is
intricately woven into defined protocols for standards of care, endpoints and outcome
measures in clinical trials, medication therapy management, and patient intake
processes. adherence.cc